Scoreboard Buy of the Week
I was over my 2% cash target in my Taxable account at the end of last week, so I made another routine buy this week. Below are the details:

Ticker: $ABBV
Account: Taxable
Date: 1/17/2023
Qty: 1 share
Price: $153.17
Avg Cost Basis: $134.20
Div Yield: 3.8%
Yield on Cost: 4.2%
Div/FCF: 45.36%
EPS: $7.51
P/E: 19.87

Scorecard: 5/6
  • vs S&P - Current price is higher than average cost basis (+11.2%), but not outperforming market, +0.5

  • FCF - Dividend Payout is less than 50% of FCF (45.4%), +1

  • Conviction - High, has been one of my best performers and a large number of patents, +1

  • Dividend Yield - 3.8% yield is higher than my portfolio average of 2.7%, but not in top 5% of >5% 0.5

  • Weighting - Sector Weighting (8.2%) and Holding Weighting (3.6%) are both less than targets of 8.5% and 4.25%, +1

  • P/E - 19.8 is less than 25, +1

PADI increased from $462.11 to $467.75 with this buy

Some other notes:
  • $ABBV up to #5 weighted holding in my Taxable account
  • Healthcare Sector and $ABBV weighting targets both met with buy
  • This is the 5th time I have purchased $ABBV, and 4th time in the past 12 months

Since my weighting targets have been met with this buy, $ABBV now drops in my Scorecard to a 4/6. We will have a new Scorecard leader this week. As of now, $T, $CARR and $PEP are tied for the top spot. We will see how things shake out tomorrow and I'll make my buy decision for next week over the weekend.
Joshua Simka's avatar
Any concerns about the patent expiration this year of Humira? Isn't it one of AbbVie's top-selling drugs?
Scoreboard Investor's avatar
@tomato they have done a good job of growing Skyrizi and Rinvoq to replace potential loss of sales from the expiring patent cliff. Their continued investment in R&D as well gives me confidence there will be more in the pipeline.

Check out Dividend Wave on Twitter. He has put out some good content on $ABBV recently
Nathan Worden's avatar
Great update!



Already have an account?